The ACTT-2 study began on May 8 and included more than 1000 patients.
Patients treated with tocilizumab were 44% less likely to progress to mechanical ventilation or death compared with placebo.
Results are provided within 15 minutes and can be read directly from the testing card.
HHS issued the amendment in order to increase access to childhood vaccines and decrease the risk of vaccine-preventable disease outbreaks as children return to daycare and school.
The FDA is expected to make a decision by the first quarter of 2021.
The FDA has approved Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate; AstraZeneca) for the maintenance treatment of chronic obstructive pulmonary disease.
The FDA has announced that it is requiring drug manufacturers for all opioid pain relievers and medicines to treat opioid use disorder to include new recommendations about naloxone to the prescribing information.
Several companies have initiated recalls of metformin extended-release tablets due to the possibility of unacceptable levels of N-Nitrosodimethylamine, a probable human carcinogen.
Results from both studies showed treatment with Qwo was associated with greater reductions in cellulite severity compared with placebo as measured by CR-PCSS and PR-PCSS scales at day 71.
Positive topline results were announced from the second pivotal phase 3 study evaluating daridorexant (Idorsia), an investigational dual orexin receptor antagonist, for the treatment of insomnia.
